Fully GMP-complient radiosynthesis of [161Tb]Tb-PSMA-1 using the miniAiO synthesizer for clinical translation.

David Kryza¹, Pierre Le Fur², Jean Noël Badel^2,3, Clément Morgat^4,5, Fouzi Khayi², Anne-Laure Giraudet²

¹Service de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France. david.kryza@lyon.unicancer.fr.

²Service de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France.

³CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France.

⁴Nuclear Medicine & Radiopharmacy Department, Bordeaux University Hospital, Bordeaux, France.

⁵INCIA, University of Bordeaux, CNRS, EPHE, UMR 5287, Bordeaux, France.

PubMed DOI

Abstract

BACKGROUND: Terbium‑161 (161Tb) is an emerging radionuclide for targeted radionuclide therapy that combines β⁻ emissions with short‑range conversion and Auger electrons, increasing its efficacy against micrometastatic and low‑volume prostate cancer. This study aimed to develop, optimize, and validate a fully automated good manufacturing practice (GMP)-compliant radiosynthesis of [161Tb]Tb-PSMA‑1 f…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.